Figure 9. Responder rates at 3 months, 6 months, 12 months and at last visit for patients who received eslicarbazepine acetate as initial monotherapy and eslicarbazepine acetate as initial adjunctive therapy. Response was defined as ≥50% seizure frequency reduction from baseline. Statistical comparisons were conducted using the Chi-squared test. Reproduced with permission from Eisai